JF
SYRE icon

Jump Financial’s Spyre Therapeutics SYRE Stock Holding History

Jump Financial’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Buy
+3,813
New +$278K ﹤0.01% 1632
2025
Q4 		– Sell
-27,100
Closed -$454K – 2285
2025
Q3 		$454K Buy
+27,100
New +$442K 0.01% 1338
2024
Q3 		– Sell
-64,900
Closed -$1.53M – 2104
2024
Q2 		$1.53M Buy
64,900
+42,100
+185% +$1.42M 0.03% 666
2024
Q1 		$865K Buy
+22,800
New +$661K 0.02% 880

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jump Financial's SYRE Position: Q2 2026 in Review

Jump Financial opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 3,813 shares worth $339K. The stake represents ﹤0.01% of the portfolio and ranks #1632 among its holdings. This is a return to the name: Jump Financial previously reported a position in SYRE as recently as Q3 2025.

Jump Financial first reported a position in SYRE in Q1 2024 and has held it in 4 quarters since. The position peaked at $1.53M in Q2 2024. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Jump Financial held 3,813 shares of Spyre Therapeutics worth $339K as of Q2 2026.
  • Spyre Therapeutics was a new Jump Financial position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Jump Financial's portfolio in Q2 2026, its #1632 holding.
  • Jump Financial first reported a position in Spyre Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Jump Financial's Spyre Therapeutics position peaked at $1.53M in Q2 2024.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.